Glynn Craig 4
4 · Hancock Jaffe Laboratories, Inc. · Filed Feb 23, 2021
Insider Transaction Report
Form 4
Glynn Craig
Chief Financial Officer
Transactions
- Award
Stock Option
2020-07-18+4,000→ 4,000 totalExercise: $10.00Exp: 2030-07-18→ Common Stock (4,000 underlying) - Award
Stock Option
2021-02-18+324,000→ 324 totalExercise: $8.20Exp: 2031-02-18→ Common Stock (324 underlying)
Footnotes (3)
- [F1]The stock option was granted pursuant to the registrant's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan").
- [F2]The stock option vests in equal quarterly installments over a three year period commencing October 18, 2020.
- [F3]The stock options vest in equal quarterly installments over a three year period, however the stock options may only become exercisable following receipt by the registrant of stockholder approval to increase the size of the Plan sufficiently to permit the exercise in full of such stock options under the Plan. If the registrant's stockholders do not approve an increase in the size of the Plan, the options will be void.